Pfizer Stock Earnings Estimates Lowered by Erste Group Bank

28 Oct 2026, 05:29 by Danessa Lincoln · The Markets Daily

Pfizer Inc. (NYSE:PFE – Free Report) – Stock analysts at Erste Group Bank dropped their FY2026 earnings per share (EPS) estimates for Pfizer in a note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $2.96 per share for the year, down from their prior forecast of $2.97. The consensus estimate for Pfizer’s current full-year earnings is $2.94 per share.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company earned $0.78 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

PFE has been the subject of several other research reports. JPMorgan Chase & Co. boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. HSBC raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Scotiabank lifted their price target on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Finally, Cantor Fitzgerald upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.72.

Check Out Our Latest Report on Pfizer

Pfizer Stock Performance

Shares of PFE stock opened at $29.82 on Monday. Pfizer has a twelve month low of $23.62 and a twelve month high of $30.44. The business has a fifty day simple moving average of $28.42 and a 200 day simple moving average of $26.72.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.8%.

Institutional Trading of Pfizer

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in Pfizer during the 2nd quarter worth approximately $1,049,602,000. BlackRock Inc. raised its stake in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. Nykredit A S bought a new position in shares of Pfizer during the second quarter valued at $205,774,000. Assenagon Asset Management S.A. raised its stake in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after acquiring an additional 5,829,204 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: ELREXFIO delivers a Phase 3 win: Pfizer said the MagnetisMM-32 study met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit for ELREXFIO in patients with relapsed or refractory multiple myeloma compared with standard regimens. The result could support broader use and future regulatory submissions. Pfizer’s ELREXFIO Phase 3 study
Positive Sentiment: FDA expands prostate-cancer approval: The FDA approved TALZENNA plus XTANDI for an earlier treatment setting in metastatic prostate cancer with homologous recombination repair gene mutations, including BRCA and non-BRCA mutations. The broader label increases the eligible patient population and commercial opportunity for the combination. TALZENNA and XTANDI FDA approval
Positive Sentiment: Analysts remain constructive: Scotiabank and Jefferies both issued “Buy” ratings, while market commentary points to the possibility of Pfizer exceeding consensus earnings expectations in its upcoming report. Scotiabank Buy rating

Pfizer Company Profile

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.